ArticleMicrobial cell factories2025
Biocatalytic cascade for the synthesis of methylphosphonate from phosphoenolpyruvate.
Article in Microbial cell factories, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundMethylphosphonate (Mpn), a building block for complex organophosphonate, is utilized in pharmaceuticals, agriculture, and chemical industries. It also serves as a critical substrate for resolving the methane paradox in ecological studies. However, current Mpn synthesis predominantly relies on chemical methods. Therefore, there is a growing interest in developing biosynthetic approaches for Mpn production.
resultsIn this study, the biosynthetic pathway of Mpn was reconstituted. Four crucial enzymes involved in the conversion of phosphoenolpyruvate (PEP) to Mpn were screened: phosphoenolpyruvate mutase (AepX), phosphonopyruvate decarboxylase (AepY), phosphonoacetaldehyde reductase (AlpJ), and methylphosphonate synthase (MpnS). Both in vitro and in vivo biocatalytic cascades were implemented. Through systematic optimization of the in vitro reaction conditions, a final Mpn conversion yield of 76% was achieved from 5 mM PEP, with an optimal enzyme concentration ratio of 5 µM AepX, 10 µM AepY, 10 µM AlpJ, and 10 µM MpnS. Building on the in vitro system, recombinant Escherichia coli strains co-expressing four enzymes were engineered as whole-cell catalysts. By employing a dual-plasmid system with varying copy numbers to regulate heterologous enzyme expression, engineered strains with distinct synthetic capabilities were obtained. The engineered strain E6 (harboring plasmids pCDFDuet-aepX-aepY and pETDuet-alpJ-mpnS) produced 7.19 mM Mpn, corresponding to a 35.95% molar conversion yield within 16 h.
conclusionsThis study established a biosynthetic method for Mpn production from PEP through enzymatic cascade, operating under mild aqueous conditions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.